EMAIL DETAILS
SUBJECT:
NW Bio
PRI: NORMAL
FROM:
H
hbiden@rosemontseneca.com
DATE:
2015-12-02 20:16:44
MSG_ID:
<CAD=XE+NV+QynRC9guAcotSBdTp+Z-1FW-RRSU7zDiB4QTO0Bhg@mail.gmail.com>
RECIPIENTS:
TO:
C
Christopher A. Boies
<cboies@bsfllp.com>
CC:
E
Eric Schwerin
<eschwerin@rosemontseneca.com>
CONTENT:
TEXT: YES |
HTML: YES
PROCESSED
Chris- Lisa tells me that BSF has signed an engagement letter with NW Bio for FDA related work but that you were following up with them on the shareholder issues. Do you know what the status of that piece is? Dennis Mehiel is a good friend and I just want to make sure we are doing all we can to be helpful. Thanks, Hunter Begin forwarded message: *From: *Lisa Barclay <LBarclay@BSFLLP.com <LBarclay@bsfllp.com>> *Date: *November 3, 2015 at 6:29:00 PM EST *To: *'Linda Powers' <lpowers@nwbio.com>, Hunter Biden <HBiden@BSFLLP.com <HBiden@bsfllp.com>> *Cc: *Dennis Mehiel <dmehiel@fourmco.com>, Les Goldman <lgoldman@nwbio.com>, Christopher Boies <cboies@BSFLLP.com <cboies@bsfllp.com>>, "' eschwerin@rosemontseneca.com'" <eschwerin@rosemontseneca.com>, Lisa Barclay <LBarclay@BSFLLP.com <LBarclay@bsfllp.com>> *Subject: **RE: Thank You ...and names for conflict check* Hi Linda: Thanks so much for your email. It was great to meet with you today, and we have already started to run conflicts checks (I had Curt Furberg and Immunicum, we may need to supplement with the other names) on the FDA-related piece. I also have already reached out to Chris Boies in New York as well to connect regarding the other issues discussed below. I know that you are looking to move forward quickly; we will be back in touch very soon. Best, Lisa *From:* Linda Powers [mailto:lpowers@nwbio.com <lpowers@nwbio.com>] *Sent:* Tuesday, November 03, 2015 5:52 PM *To:* Lisa Barclay; Hunter Biden *Cc:* Dennis Mehiel; Les Goldman *Subject:* Thank You ...and names for conflict check Dear Lisa, Hunter and Eric: Thanks so much for making time this morning for our meeting. It was great talking with you. We appreciated the opportunity to describe our Company and our need for some special FDA-related help in connection with the screening hold on our Phase III trial. Your comments and questions were insightful and helpful, and we hope to be able to work with you on this, assuming that the conflicts check clears. The names that we think are relevant for the conflicts check are Dr. Curt Furberg (the former DMC chairman), Immunicum (the undisclosed competitor company, co-founded by Curt’s brother), Bengt Furberg (brother of Curt), and Michael Thorn (the DMC Secretary, who attempted to send us unblinded info without our knowledge or consent). As far as we are aware, there is no company association for Curt Furberg. Mr. Thorn is President of a company called Statistical Resources, Inc. Both Curt Furberg and Mr. Thorn are located in N.C., I believe. Also thanks very much for your suggestion about potentially working with your New York partners on our other issue, about the massive bear raid attacks that have been directed at our Company over the last couple of years, with increasing intensity, including naked shorting, other forms of stock manipulation, and extensive media and social media smear campaigns. We would love to work with them on this issue. We don’t know particular names of the hedge fund predators. So, we don’t know particular names to suggest for conflicts check for that issue. We look forward to a follow-up discussion with you after the conflicts check. Kind regards, Linda (Please forward this email to Eric – we didn’t get an email address for him. Thanks.) ------------------------------ The information contained in this electronic message is confidential information intended only for the use of the named recipient(s) and may contain information that, among other protections, is the subject of attorney-client privilege, attorney work product or exempt from disclosure under applicable law. If the reader of this electronic message is not the named recipient, or the employee or agent responsible to deliver it to the named recipient, you are hereby notified that any dissemination, distribution, copying or other use of this communication is strictly prohibited and no privilege is waived. If you have received this communication in error, please immediately notify the sender by replying to this electronic message and then deleting this electronic message from your computer. [v.1
METADATA:
THREAD:
INDEX:
Adhhnwk/9Zad6i41Tpyt5iU4jp0GUA==